158 related articles for article (PubMed ID: 37218395)
1. Effect of pituitary-dependent hypercortisolism on the survival of dogs treated with radiotherapy for pituitary macroadenomas.
Rapastella S; Morabito S; Sharman M; Benoit J; Schiavo L; Morris J; Dobson JM; Scudder CJ
J Vet Intern Med; 2023; 37(4):1331-1340. PubMed ID: 37218395
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of the addition of pasireotide to traditional adrenal-directed treatment for dogs with pituitary-dependent hyperadrenocorticism secondary to macroadenoma: 9 cases (2013-2015).
Lottati M; Bruyette DS
J Am Vet Med Assoc; 2018 Jun; 252(11):1403-1408. PubMed ID: 29772978
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Survival Times for Dogs with Pituitary-Dependent Hyperadrenocorticism in a Primary-Care Hospital: Treated with Trilostane versus Untreated.
Nagata N; Kojima K; Yuki M
J Vet Intern Med; 2017 Jan; 31(1):22-28. PubMed ID: 27906457
[TBL] [Abstract][Full Text] [Related]
4. Long-term survival with stereotactic radiotherapy for imaging-diagnosed pituitary tumors in dogs.
Hansen KS; Zwingenberger AL; Théon AP; Kent MS
Vet Radiol Ultrasound; 2019 Mar; 60(2):219-232. PubMed ID: 30575174
[TBL] [Abstract][Full Text] [Related]
5. Pituitary macroadenomas and macroadenocarcinomas in dogs treated with mitotane for pituitary-dependent hyperadrenocorticism: 13 cases (1981-1986).
Nelson RW; Ihle SL; Feldman EC
J Am Vet Med Assoc; 1989 Jun; 194(11):1612-7. PubMed ID: 2753785
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of cobalt 60 radiotherapy in dogs with pituitary-dependent hyperadrenocorticism.
Goossens MM; Feldman EC; Theon AP; Koblik PD
J Am Vet Med Assoc; 1998 Feb; 212(3):374-6. PubMed ID: 9470046
[TBL] [Abstract][Full Text] [Related]
7. Pituitary size alteration and adverse effects of radiation therapy performed in 9 dogs with pituitary-dependent hypercortisolism.
Sawada H; Mori A; Lee P; Sugihara S; Oda H; Sako T
Res Vet Sci; 2018 Jun; 118():19-26. PubMed ID: 29339329
[TBL] [Abstract][Full Text] [Related]
8. One-year follow-up evaluation of magnetic resonance imaging of the brain in dogs with pituitary-dependent hyperadrenocorticism.
Bertoy EH; Feldman EC; Nelson RW; Dublin AB; Reid MH; Feldman MS
J Am Vet Med Assoc; 1996 Apr; 208(8):1268-73. PubMed ID: 8635969
[TBL] [Abstract][Full Text] [Related]
9. Clinical features of muscle stiffness in 37 dogs with concurrent naturally occurring hypercortisolism.
Golinelli S; Fracassi F; Bianchi E; Pöppl ÁG; Miceli DD; Benedicenti L; De Marco V; Cook AK; Espada Castro L; Ramsey I; Seo KW; Cantile C; Gandini G; Hulsebosch SE; Feldman EC
J Vet Intern Med; 2023 Mar; 37(2):578-585. PubMed ID: 36798032
[TBL] [Abstract][Full Text] [Related]
10. Adrenocorticotropic hormone-producing pituitary adenoma with pituitary apoplexy treated by surgical decompression: a case report.
Tanaka S; Suzuki S; Oishi M; Soeta S; Namiki R; Hara Y
BMC Vet Res; 2022 Nov; 18(1):397. PubMed ID: 36369011
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors for outcome after transsphenoidal hypophysectomy in dogs with pituitary-dependent hyperadrenocorticism.
Hanson JM; Teske E; Voorhout G; Galac S; Kooistra HS; Meij BP
J Neurosurg; 2007 Oct; 107(4):830-40. PubMed ID: 17937231
[TBL] [Abstract][Full Text] [Related]
12. TRH-induced secretion of adrenocorticotropin and cortisol in dogs with pituitary-dependent hypercortisolism.
Pijnacker T; Knies M; Galac S; Sanders K; Mol JA; Kooistra HS
Vet Q; 2018 Dec; 38(1):72-78. PubMed ID: 30362899
[TBL] [Abstract][Full Text] [Related]
13. Assessment of selegiline and trilostane combined therapy efficacy for canine pituitary-dependent hypercortisolism treatment: A pilot randomized clinical trial.
de Carvalho GLC; Meirelles L; da Silva CC; Neto WS; Furtado PV; Machado L; de Moura Martins FS; da Silva Mello FP; de Faria Valle S; Pöppl ÁG
Res Vet Sci; 2022 Dec; 150():107-114. PubMed ID: 35809414
[TBL] [Abstract][Full Text] [Related]
14. The Influence of Pituitary Size on Outcome After Transsphenoidal Hypophysectomy in a Large Cohort of Dogs with Pituitary-Dependent Hypercortisolism.
van Rijn SJ; Galac S; Tryfonidou MA; Hesselink JW; Penning LC; Kooistra HS; Meij BP
J Vet Intern Med; 2016 Jul; 30(4):989-95. PubMed ID: 27425149
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors for survival in dogs with pituitary-dependent hypercortisolism treated with trilostane.
Fracassi F; Corradini S; Floriano D; Boari A; Aste G; Pietra M; Bergamini PF; Dondi F
Vet Rec; 2015 Jan; 176(2):49. PubMed ID: 25170036
[TBL] [Abstract][Full Text] [Related]
16. Utility of a corticotropin-releasing hormone test to differentiate pituitary-dependent hyperadrenocorticism from cortisol-producing adrenal tumors in dogs.
Tanaka S; Suzuki S; Sato A; Teshima T; Mori A; Sako T; Tanaka A; Hara Y
J Vet Intern Med; 2022 Jan; 36(1):29-38. PubMed ID: 34859496
[TBL] [Abstract][Full Text] [Related]
17. Survival of dogs with pituitary-dependent hyperadrenocorticism treated twice daily with low doses of trilostane.
García San José P; Arenas Bermejo C; Alonso-Miguel D; González Sanz S; Clares Moral I; Portero Fuentes M; Pérez-Alenza MD
Vet Rec; 2022 Aug; 191(3):e1630. PubMed ID: 35460587
[TBL] [Abstract][Full Text] [Related]
18. Effects of trilostane on the pituitary-adrenocortical and renin-aldosterone axis in dogs with pituitary-dependent hypercortisolism.
Galac S; Buijtels JJCWM; Mol JA; Kooistra HS
Vet J; 2010 Jan; 183(1):75-80. PubMed ID: 19042143
[TBL] [Abstract][Full Text] [Related]
19. Na(+), K(+)-ATPase content in skeletal muscle of dogs with pituitary-dependent hyperadrenocorticism.
Schotanus BA; Meij BP; Vos IH; Kooistra HS; Everts ME
Domest Anim Endocrinol; 2006 May; 30(4):320-32. PubMed ID: 16202554
[TBL] [Abstract][Full Text] [Related]
20. Effects of radiotherapy on pituitary corticotroph macrotumors in dogs: a retrospective study of 12 cases.
de Fornel P; Delisle F; Devauchelle P; Rosenberg D
Can Vet J; 2007 May; 48(5):481-6. PubMed ID: 17542365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
